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CLINICAL SCIENCE
Incidence, Timing, and Determinants of Bacterial
Pneumonia Among HIV-Infected Patients: Data From the
ICONA Foundation Cohort
Cristina Mussini, MD,* Laura Galli, MD,† Alessandro C. Lepri, PhD,‡ Andrea De Luca, MD,§
Andrea Antinori, MD,k Raffaella Libertone, MD,k Gioacchino Angarano, MD,¶ Paolo Bonfanti, MD,#
Antonella Castagna, MD,† and Antonella d’Arminio Monforte, MD,** for the ICONA
Foundation Study Group
Background: The aim of the study was to evaluate incidence and
determinants of bacterial pneumonia (BP) after starting combination
antiretroviral therapy (cART) in the Italian Cohort of Antiretroviral-
Naive Patients.
Methods: Patients free from BP at cART initiation enrolled
between 1996 and 2011 were analyzed. Kaplan–Meier curves were
calculated to estimate the time to the ﬁrst episode of BP; uni- and
multivariable Cox proportional hazard models, with time-updated
covariates, were applied to identify the risk factors of the ﬁrst epi-
sode of BP.
Results: Four thousand nine hundred forty-two patients were
followed for a median of 63.7 months (interquartile range: 23.6,
106.7); 73% were men, median age 36 years (interquartile range: 32,
42), 35% hepatitis C virus antibody positive, 28% smokers, 15%
with an AIDS diagnosis (not BP) before cART, 46% with nadir
CD4+ T-cell count #200 cells per microliter. During 27,569 person
years, 137 patients developed 156 BPs, for a crude incidence of 5.66
[95% conﬁdence interval (CI): 4.81 to 6.62] per 1000 person years.
The probabilities of ﬁrst BP at 3, 5, 10, and 14 years from cART
initiation were 2.0% 6 0.22%, 2.9% 6 0.28%, 4.3% 6 0.42%, and
5.7% 6 0.75%, respectively. The occurrence of a ﬁrst BP was asso-
ciated with low nadir CD4+ [hazard ratios (HR) (per 100 cells/mL
higher) = 0.86, 95% CI: 0.79 to 0.94], low current CD4+ [HR (per
100 cells/mL higher) = 0.88, 95% CI: 0.84 to 0.92], high CD8+ [HR
(per 100 cells/mL higher) = 1.02, 95% CI: 1.01 to 1.03], low hemo-
globin [HR (per g/dL higher) = 0.74, 95% CI: 0.71 to 0.78], and
unfavorable virological outcome [HR (HIV-RNA .50 vs ,50 cop-
ies/mL) = 1.29, 95% CI: 1.04 to 1.60] in addition to older age,
male gender, non-Italian nationality, smoking, and longer time to
cART initiation.
Conclusions: BP is an infrequent clinical event in the cART era
and is associated with traditional risk factors, viroimmunological
failure to cART, and low hemoglobin.
Key Words: bacterial pneumonia, incidence, risk factors, antiretro-
viral-naive patients
(J Acquir Immune Deﬁc Syndr 2013;63:339–345)
INTRODUCTION
In the era of the combination antiretroviral therapy
(cART), bacterial pneumonia (BP) is still a major cause of
morbidity and mortality of HIV-infected patients.1,2 Recurrent
BP was considered a marker of impaired immune function
and therefore was included in the 1993 Centers for Disease
Control and Prevention classiﬁcation as an AIDS-deﬁning
illness.3 In industrialized countries, approximately 10% of
the causes of severe morbidity and 5% of the causes of death
of HIV+ patients are related to BP,1,2 and even a single BP
episode is associated with increased morbidity and mortal-
ity.4–6 In the last years, even if a marked reduction in
AIDS-associated opportunistic infections is well docu-
mented,7 the incidence of BP did not decrease in parallel
with that of other infections and high rates of BP have
been reported.8,9
Reduction in the long-term survival after BP may be
inﬂuenced by different factors, including increased viral
replication and viral burden, increased inﬂammation, and
changes in immune status.10 The degree of immunosuppres-
sion has been associated with increased risk of pneumonia.
However, although the risk to develop BP is higher among
HIV+ patients with low CD4 cell counts, rates of BP remain
elevated even among persons with a level of CD4 .500 cells
per microliter.11 Furthermore, in a recent follow-up of the
Strategies for Management of Antiretroviral Therapy study
group, the increased risk of opportunistic diseases correlated
with the viral load and was independent of the CD4+ cell
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count.12 Multiple risk factors contribute to increase the risk of
pneumonia, including age, intravenous drug use, smoking of
illicit drugs, and alcoholism.9,13–15 Tobacco smoking, which is
highly prevalent in HIV-infected populations, is also indepen-
dently associated with an increased risk of BP.13
To investigate the incidence, timing, and determinants of
BP, in HIV+ patients of ICONA (Italian Cohort of Antiretro-
viral-Naive Patients), we have evaluated the rate and risk factors
for developing at least one episode of BP after starting cART.
METHODS
Study Population
The study population included patients who, at the
beginning of cART, had never experienced BP and have been
enrolled in the multicenter ICONA Foundation Study, during
the period August 1996 to June 2011. Data of the ICONA are
prospectively collected and centrally stored into a database:
each center is asked 4 times per year (ie, every 3 months) to
send the data prospectively collected on each patient included
in the cohort. Data collected include information on comor-
bidities, thus including pulmonary diseases. In addition, data
monitoring is performed once a year to ensure accurate and
complete data collection.
Demographic and clinical characteristics and the data
regarding immunological, virological, and hematological
parameters (hemoglobin, white blood cells, neutrophils, and
platelets) were extracted from the ICONA database. Informa-
tion on cART included type of ﬁrst-line therapy [mono/dual
(ART initiation with 1 or 2 antiretroviral drugs) versus highly
active antiretroviral therapy (HAART) (ART initiation with
$3 antiretroviral drugs)] and years of cumulative exposure to
cART. Data on pneumococcal vaccination were not collected.
Definition of BP
The diagnosis of BP was ascertained at each center of
ICONA by history and medical and radiological record
reviews; the diagnosis was based on the presence of a pro-
gressive inﬁltrate on a chest radiograph, clinical response to
antibacterial medications, and, when available, on a sputum
culture positive for any microorganism. The following
diagnoses of pneumonia were excluded: Pneumocystis jiro-
veci pneumonia, tuberculosis or other mycobacteria, and viral
pneumonia. Case deﬁnitions were based on the evaluation of
the treating physicians.
Statistical Analysis
Results were described as median and interquartile
range (IQR), or number of cases (percent), as appropriate. The
crude incidence rates of BP, with the corresponding 95%
conﬁdence intervals (CIs), were calculated per 1000 person
years of follow-up (PYFU) as the total number of BP
episodes divided by the time contributed by all subjects
(in this calculation, time was censored at the last patient’s
cohort visit).
Follow-up was counted from the date of the cART start
(baseline) to the date of ﬁrst BP, for patients who had at least
one event, or the date of last patient’s cohort visit if BP did
not occur. Patients with a ﬁrst BP before ART start were
excluded from the analyses.
Virological suppression was deﬁned by the achieve-
ment of at least one value of HIV-RNA ,50 copies per
milliliter after the start of cART; time to virological suppres-
sion was deﬁned as the interval time between the start of
cART and the achievement of the ﬁrst HIV-RNA ,50 copies
per milliliter. Two consecutive values of HIV-RNA .50
copies per milliliter after the achievement of virological sup-
pression were used to deﬁne virological failure; time to viro-
logical failure was deﬁned as the interval time between the
achievement of the ﬁrst HIV-RNA ,50 copies per milliliter
and the ﬁrst of 2 consecutive values of HIV-RNA.50 copies
per milliliter.
Associations between clinical variables and the occur-
rence of ﬁrst BP were examined using x2 or Fisher exact tests.
The Wilcoxon rank sum test was applied to detect differences
among subjects with or without BP with respect to distribu-
tions of continuous variables. The Wilcoxon sign rank test
was used to detect signiﬁcant changes from the start of cART
for the laboratory parameters.
Time to the ﬁrst episode of BP (since cART initiation)
was estimated by Kaplan–Meier curves and compared by the
log rank test. The relation between demographic, clinical, and
laboratory parameters and the occurrence of the ﬁrst BP was
analyzed by uni- and multivariable Cox proportional hazard
models. The following characteristics were considered: age,
gender (male vs female), education (elementary vs interme-
diate vs unknown), mode of HIV transmission (intravenous
drug users, IDU, vs other), hepatitis C virus (HCV) antibody
(positive vs negative vs unknown), a diagnosis of AIDS
before cART (yes vs no), nadir CD4+ (per 100 cells/mm3
higher), smoking (yes vs no vs unknown), nationality (Italian
vs non-Italian), months since enrollment to cART start,
CD4+, CD8+, HIV-RNA (#50 vs .50 copies/mL), hemoglo-
bin, white blood cells, platelets, and neutrophils; smoking
status, CD4+, CD8+, HIV-RNA, hemoglobin, white blood
cells, platelets, and neutrophils were examined as time-depen-
dent variables. Factors notably known to be or those that were
found (P , 0.05) associated with the occurrence of BP were
entered into the multivariable model. Hazard ratios (HR) and
the corresponding 95% CIs were reported.
All tests were 2 sided, and a P value , 0.05 was con-
sidered statistically signiﬁcant. Analyses were performed using
the SAS software (release 9.2; SAS Institute, Cary, NC).
RESULTS
A total of 4942 patients started cART without having
had a BP and were included in the analyses. During 27,569
person years of observation [median follow-up: 5.03 (IQR:
1.84, 8.62) years], 156 BPs occurred in 137 patients. Multiple
episodes were infrequent: 124 (90%) patients had 1 episode,
11 (8%) had 2 episodes, 1 (,1%) had 3 episodes, and 1
(,1%) had 7 episodes. The crude rate of BP was 5.66
(95% CI: 4.81 to 6.62) episodes per 1000 person years.
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Etiology of BP was unknown in 80 cases, whereas
among the other 57 patients, the most frequent pathogens were
Streptococcus pneumoniae (23), followed by Staphylococcus
aureus (9), Haemophilus spp (7), Klebsiella pneumonia (4),
Legionella (4), Pseudomonas aeruginosa (5), Escherichia coli
(2), Mycoplasma pneumonia (1), Chlamydia (1), and Acyneto-
bacter baumannii (1).
Table 1 shows the baseline characteristics of the
patients classiﬁed as those who developed at least 1 BP
(N = 137) and those who did not (N = 4805).
Subjects who experienced BP were more frequently IDU
and coinfected with HCV, had a lower education degree, lower
percentages of CD4+ T cells, and lower values of nadir CD4+;
hemoglobin values were comparable with those subjects with-
out BP. Eight hundred twenty-eight (17%) patients started
a mono/dual ART (and, subsequently, HAART), whereas
4114 started HAART (83%) as ﬁrst-line therapy. Three hun-
dred eighteen (6%), 1563 (32%), and 3061 (62%) patients
started a nucleoside reverse transcriptase inhibitor–based, non-
nucleoside reverse transcriptase inhibitor–based, or protease
inhibitor–based cART, respectively. There were 828 subjects
who started a mono/dual ART and switched to HAART after
16.4 (IQR: 5.9, 39.6) months. In these patients, the ﬁrst episode
of BP occurred after a median of 1.47 (IQR:20.32, 3.12) years
after the beginning of HAART.
Death occurred in 21 (15%) and 272 (6%) subjects with
or without BP, respectively (P , 0.0001). Eleven causes of
death were HIV related, 3 related to other diseases, 2 cardio-
vascular events, 1 liver-related death, and 4 unknown. Among
patients with BP, death occurred after a median of 12.6 (IQR:
0.3, 34.4) months since the ﬁrst episode of BP.
Concerning CD4 counts, among subjects with at least one
event at the time of the ﬁrst BP occurrence, 46 (34%) had#200
cells per microliter, 31 (23%) had 201–350 cells per microliter,
and 60 (44%) had .350 cells per microliter, whereas median
HIV-RNA was 2.79 (1.70–4.65) (log10 copies/mL).
Among patients who developed BP, the median follow-
up before the ﬁrst episode of BP was 22.7 (IQR: 7.2, 56.8)
months; during this period, signiﬁcant immunological
changes were observed [CD4+: 48 (251, +199) cells/mL,
P = 0.002; CD8+: 36 (2378, +304) cells/mL, P = 0.894].
Upon cART initiation, 758 patients (16%) never
achieved virological suppression: 43 (34%) among those
who developed BP and 715 (15%) among those who did not,
respectively (P , 0.0001). Out of the 4184 (84%) patients
who reached virological success during follow-up [median
time to virological suppression: 6.3 (IQR: 3.4, 15.7) months],
no signiﬁcant differences were observed among subjects with
or without BP (P = 0.285). At the time of the ﬁrst BP, 48
(35%) patients had an undetectable viral load and 89 (65%)
had a positive viremia.
First BP episode occurred 2.8 (IQR: 1.0, 5.4) years after
the achievement of virological suppression, when reached.
Moreover, the time to the ﬁrst BP was shorter among patients
who maintained virological suppression (n = 49), when
compared with those who did not (n = 45) [1.8 (IQR: 0.9, 3.5)
years and 6.0 (IQR: 3.8, 9.3) years, respectively, P , 0.0001].
Overall, the probabilities (6 standard error) of the ﬁrst
BP at 3, 5, 10, and 14 years since cART initiation were 2.0%
6 0.22%, 2.9% 6 0.28%, 4.3% 6 0.42%, and 5.7% 6
0.75%, respectively. The probability of having BP was similar
among strata (quartiles) of calendar year of cART initiation
(1996–1998, 1999–2000, 2001–2006, and 2007–2011; log
rank test: P = 0.111; data not shown).
As shown in Figure 1, the probability of ﬁrst BP was
higher in patients with lower values of nadir CD4+ (nadir
CD4+ #200 vs .200 cells/mm3, P = 0.050), in the presence
of a HCV coinfection (positive vs negative, P = 0.006), and
among smokers (smoker vs nonsmoker, P , 0.0001). Uni-
variable and multivariable HR were evaluated to ﬁnd out
factors associated with BP (Table 2). At multivariable analy-
sis, as expected, traditional risk factors for BP were predictive
of the event: the risk of ﬁrst BP increased with age and was
more likely among men as compared with women, among
smokers as compared with nonsmokers, among non-Italian
as compared with Italian subjects. In addition, BP was more
likely to occur in subjects with positive HIV viremia, low
values of nadir CD4+, low values of hemoglobin, low values
of CD4+, high values of CD8+, and delayed cART initiation.
DISCUSSION
The present study has shown that BP is a relatively
uncommon event among HIV-infected patients. Data on BP
incidence are not consistent among different studies, varying
from 8.5 to 28.0 PYFU.7,11,15 In our cohort, the rate of inci-
dence was much lower, that is, 5.66 per 1000 PYFU. Because
patients enrolled in ICONA are Italians, we cannot exclude
a role for a milder climate.
Concerning the etiology, it was impossible to establish
a causative agent in all patients. However, S. pneumoniae
remains the most frequent pathogen, as previously
described.15 This is particularly relevant because either pri-
mary infection or recurrent episodes of S. pneumoniae can be
successfully prevented by vaccination even in patients with
HIV infection, especially when the vaccine is administered to
patients with high CD4+ T-cell count.16–18 Concerning risk
factors for the development of BP, we found signiﬁcant asso-
ciations with demographic characteristics, HIV infection–
related factors (with immune suppression and viremia playing
a major role), and lifestyle–related factors (with smoking
playing a well-known main role).
The importance of age on BP has already been reported
by Goulet et al19: older HIV-infected veterans, aged $50
years, had higher odd of pulmonary disease than younger
HIV-infected veterans or older HIV-uninfected veterans.
We found that men were more likely to develop BP
than women, according to previous data showing that such
incidence is higher in men than in women, in all age groups
considered.20,21 These differences may be a consequence of
genetic differences linked to X-chromosome, in the expres-
sion of steroid hormones, and ﬁnally in anatomy.22 Italian
subjects were less likely to experience BP: this might be
related to a high socioeconomic status, with an easier access
to the National Health Care System. It is to note that most
immigrants came from African countries and are not used to
Italian winter temperatures, which are milder than in Northern
Europe, but much colder than in their countries of origin.
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TABLE 1. Demographic and Clinical Characteristics of the Study Patients at cART Initiation
Characteristic Overall (N = 4942) With BP (N = 137) Without BP (N = 4805) P
Age (yrs) 37 (32–43) 37 (33–42) 37 (32–43) 0.821*
Gender 0.846†
Males 3586 (72.6%) 101 (73.7%) 3485 (72.5%)
Females 1536 (27.4%) 36 (26.3%) 1320 (27.5%)
Nationality 0.989†
Italian 4499 (91.0%) 127 (92.7%) 4372 (91.0%)
Non-Italian 443 (9.0%) 10 (7.3%) 433 (9.0%)
Education 0.015†
Elementary degree 2075 (42.0%) 72 (52.5%) 2003 (41.7%)
Intermediate degree 1520 (30.8%) 26 (19.0%) 1494 (31.1%)
Unknown 1347 (27.2%) 39 (28.5%) 1308 (27.2%)
Smoking ,0.0001†
Yes 2252 (45.6%) 66 (48.2%) 2186 (45.5%)
No 2160 (43.7%) 25 (18.2%) 2135 (44.4%)
Unknown 530 (10.7%) 46 (33.6%) 484 (10.1%)
Alcohol consumption 0.999†
Yes 742 (15.0%) 20 (14.6%) 722 (15.0%)
No 4200 (85.0%) 117 (85.4%) 4083 (85.0%)
Mode of HIV transmission ,0.0001†
IDU 1389 (27.9%) 63 (46.0%) 1326 (27.6%)
MSM 1261 (25.5%) 16 (11.7%) 1245 (25.9%)
Heterosexual 1960 (39.7%) 47 (34.3%) 1913 (39.8%)
Other 69 (1.4%) 1 (0.7%) 68 (1.4%)
Unknown 263 (5.3%) 10 (7.3%) 253 (5.3%)
HCV antibody 0.002†
Positive 1741 (35.2%) 67 (48.9%) 1674 (34.8%)
Negative 2819 (57.0%) 59 (43.1%) 2760 (57.4%)
Unknown 382 (7.7%) 11 (8.0%) 371 (7.7%)
HBsAg 0.067†
Positive 357 (7.2%) 9 (6.6%) 348 (7.2%)
Negative 4196 (84.9%) 110 (80.3%) 4086 (85.0%)
Unknown 389 (7.9%) 18 (13.1%) 371 (7.7%)
Diagnosis of AIDS before cART‡ 0.089†
Yes 747 (15.1%) 28 (20.4%) 719 (15.0%)
No 4195 (84.9%) 109 (79.6%) 4086 (85.0%)
Nadir CD4+ 220 (97–317) 173 (38–307) 221 (99–317) 0.014*
#200 (cells/mm3) 2223 (45.0%) 71 (51.8%) 2152 (44.8%) 0.049†
.200 (cells/mm3) 2719 (55.0%) 66 (48.2%) 2653 (55.2%)
CD4+ (cells/mm3) 280 (143–411) 241 (88–395) 281 (144–413) 0.156*
CD4 (%) 17.9 (11.0–25.0) 15.6 (8.0–22.6) 18.0 (11.0–25.0) 0.019*
CD8+ (cells/mm3) 832 (550–1197) 805 (540–1268) 832 (550–1192) 0.971*
CD8 (%) 56.4 (48.0–65.4) 56.1 (48.0–67.0) 56.5 (48.0–65.2) 0.804*
HIV-RNA (log10 copies/mL) 4.79 (4.24–5.28) 4.94 (4.20–5.28) 4.78 (4.24–5.28) 0.850*
Hemoglobin (g/dL) 13.5 (12.2–14.7) 13.0 (11.8–14.3) 13.5 (12.2–14.7) 0.032*
White blood cells (106 cells/mm3) 4860 (3800–6015) 4710 (3800–6460) 4865 (3800–6000) 0.643*
Neutrophils (106 cells/mm3) 2500 (1882–3350) 2468 (1810–3430) 2500 (1887–3350) 0.967*
Platelet (109 cells/L) 184 (142–229) 181 (143–230) 184 (142–229) 0.840*
AST (U/L) 29 (21–45) 34 (22–56) 28 (21–45) 0.027*
ALT (U/L) 30 (20–51) 32 (18–60) 30 (20–51) 0.590*
Months since enrollment to cART start (mo) 1.2 (0–12.9) 1.3 (0–11.7) 1.2 (0–12.9) 0.773*
*Wilcoxon rank sum test to detect signiﬁcant differences between patients with or without BP in relation to continuous variables.
†x2 Test to detect signiﬁcant differences between patients with or without BP in relation to categorical variables.
‡The diagnosis did not include BP.
IDU, intravenous drug users; MSM, men who have sex with men; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HBsAg, hepatitis B surface Antigen.
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Concerning CD4, either nadir or current CD4+ T-cell
count was associated with the development of BP; it is to note
that patients with a CD4+ T-cell count .350 cells per micro-
liter developed BP. The fact that immune suppression could
favor the onset of BP was already known because recurrent
episodes are considered an AIDS-deﬁning event.
In our study, most patients who developed BP had
a detectable viral load, likely because of treatment failure or
treatment discontinuation. Viral load has a role, which is
independent from immune deﬁciency. This is conﬁrmed by
data from Collaboration of Observational HIV Epidemiological
Research in Europe showing that patients with a CD4+ T-cell
count lower than 200 cells per microliter could be protected
from a ﬁrst or a recurrent episode of P. jiroveci pneumonia, in
the absence of prophylaxis, if they have an undetectable HIV
plasma viremia.23 These data go in the same direction of those
from the Strategies for Management of Antiretroviral Therapy
trial: indeed, the inﬂammation related to HIV replication could
favor the onset of AIDS and non-AIDS diseases.12 The earlier
BP occurrence among patients who achieved and maintained
virological suppression as compared with those who did not
was mainly related to a delayed cART initiation and slightly
higher HIV-RNA values at cART initiation observed in these
patients (data not shown).
Concerning blood markers, anemia has been related to the
onset of BP, and indeed, our results conﬁrmed the association of
anemia with a poorer outcome. Most studies evidenced a possible
role of anemia on survival,24,25 and anemia was recently included
in a combined prognostic index for survival, the Veterans Ageing
Cohort Study (VACS) index,26,27 and in several patients can
improve during ART.28 If anemia persists or develops after treat-
ment, different phenomena can be suspected, including a poor
adherence, emerging HIV resistance, or additional causes of
chronic inﬂammation.27 It is also possible that this marker may
be a proxy of a general impairment of the bone marrow that
could lead to a worse prognosis not only in HIV infection but
also in other chronic diseases, such as cancer.29
Recurrent episodes of BP are a risk factor for the
development of lung cancer,30 and at the beginning of cART
era, there were some data showing an increase in the inci-
dence of recurrent BP. However, our data show that BP is, at
present, a relatively rare event.31 Tobacco smoking is a very
dangerous habit, being a major risk factor for cardiovascular
events, osteoporosis, and also for pulmonary pathologies
increasing risk of pneumococcal bacteremia and invasive
pneumococcal disease.32,33 Because approximately 40%–
70% of people living with HIV smoke, in contrast with
21% who smoke among all US adults,34,35 clinicians should
use all available strategies to convince patients to smoking
cessation (being well aware that this is not easy at all).
We found that the risk of BP increased with a longer
time spent without antiretroviral treatment because a delayed
cART initiation slightly increased the chance of developing
BP. The beneﬁcial effects of early ART initiation have
already been reported in previous studies,36–39 showing
that the excess of AIDS or death associated with deferred
initiation of combination therapy became more pronounced,
that is, when the CD4+ T-cell count threshold for starting
treatment decreased.
FIGURE 1. Time to first BP according to smoking status at
cART initiation (smoker vs nonsmoker), HCV antibody (positive
vs negative), nadir CD4+ (#200 vs .200 cells/mL).
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Our study has some possible limitations, including: (1)
the fact that ICONA is a cohort that includes Departments of
Infectious Diseases in main universities or hospitals. Because
some episodes of BP could have been treated by general
practitioners, we cannot exclude that underreporting the
incidence of BP may have occurred; (2) ICONA collects main
demographic, clinical, and laboratory data but does not have
a speciﬁc form for BP or other pulmonary diseases. Thus, for
the analysis shown here, we could use only the data recorded in
the cohort database; (3) we could not collect data on
pneumococcal vaccination, and thus, we could not evaluate
a possible protective role and its inﬂuence on the low incidence
of BP; (4) we had no data on chronic obstructive pulmonary
disease, and thus, we could not evaluate a possible role of this
disease as a risk factor for BP in our population; and (5) ﬁnally,
our study does not have the statistical power to evaluate the
risk factors for recurrences. However, it is possible that cART,
as in the case of other opportunistic infections, may have a role
in preventing them.23
In conclusion, even considering the possible problem of
underreporting, it seems that BP is uncommon among HIV+
patients living in Italy and enrolled in ICONA. Classical risk
factors as immune deﬁciency and smoking are associated with
BP onset, but a major role seems to be played by uncontrolled
HIV viremia and anemia. Thus, to prevent BP, clinicians
should prescribe pneumococcal vaccine and cART and sug-
gest strategies for smoking cessation to their patients.
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